BACKGROUND: The objective was to determine the prognostic value of functional imaging (FI) in predicting outcome of patients with recurrent/refractory Hodgkin lymphoma (HL) before undergoing high-dose chemotherapy with autologous stem cell transplantation (ASCT). METHODS: Clinical and imaging data were retrospectively reviewed in 211 consecutive patients treated with ASCT from February 1993 to May 2004. The FI results were correlated with progression-free survival (PFS) and overall survival (OS) using Kaplan-Meier survival analysis. RESULTS: Responses were assessed by conventional criteria and evaluated by positron emission tomography (PET) (n = 68) and gallium scans (n = 144) before ASCT. A complete response (CR) or unconfirmed CR (CRu) was seen in 51% of patients, a partial response (PR) in 41% of patients, and stable or progressive disease in 7% of patients. FI was positive in only 6 of 110 (5%) of CR/CRu patients, in 48 of 86 (56%) of PR patients, and in all 3 patients with progressive disease. The 3-year PFS was 69% for patients with negative FI versus 23% for patients with positive FI (P < .0001). The 3-year OS rates were 87% and 58%, respectively (P < .0001). The 3-year PFS for patients in PR with negative FI was 51% comparable to patients in CR (76%) versus 27% for patients in PR with positive FI (P < .0001). In a multivariate model, positive FI was found to be independently prognostic of PFS. CONCLUSIONS: Pretransplant FI status predicts outcome in patients with recurrent/refractory HL. Positive FI confers a poor prognosis, independent of other traditional presalvage prognostic factors. Copyright 2007 American Cancer Society.
BACKGROUND: The objective was to determine the prognostic value of functional imaging (FI) in predicting outcome of patients with recurrent/refractory Hodgkin lymphoma (HL) before undergoing high-dose chemotherapy with autologous stem cell transplantation (ASCT). METHODS: Clinical and imaging data were retrospectively reviewed in 211 consecutive patients treated with ASCT from February 1993 to May 2004. The FI results were correlated with progression-free survival (PFS) and overall survival (OS) using Kaplan-Meier survival analysis. RESULTS: Responses were assessed by conventional criteria and evaluated by positron emission tomography (PET) (n = 68) and gallium scans (n = 144) before ASCT. A complete response (CR) or unconfirmed CR (CRu) was seen in 51% of patients, a partial response (PR) in 41% of patients, and stable or progressive disease in 7% of patients. FI was positive in only 6 of 110 (5%) of CR/CRu patients, in 48 of 86 (56%) of PR patients, and in all 3 patients with progressive disease. The 3-year PFS was 69% for patients with negative FI versus 23% for patients with positive FI (P < .0001). The 3-year OS rates were 87% and 58%, respectively (P < .0001). The 3-year PFS for patients in PR with negative FI was 51% comparable to patients in CR (76%) versus 27% for patients in PR with positive FI (P < .0001). In a multivariate model, positive FI was found to be independently prognostic of PFS. CONCLUSIONS: Pretransplant FI status predicts outcome in patients with recurrent/refractory HL. Positive FI confers a poor prognosis, independent of other traditional presalvage prognostic factors. Copyright 2007 American Cancer Society.
Authors: Jacob P Smeltzer; Amanda F Cashen; Qin Zhang; Andrew Homb; Farrokh Dehdashti; Camille N Abboud; John F Dipersio; Keith E Stockerl-Goldstein; Geoffrey L Uy; Ravi Vij; Peter Westervelt; Nancy L Bartlett; Todd A Fehniger Journal: Biol Blood Marrow Transplant Date: 2011-05-03 Impact factor: 5.742
Authors: M Damlaj; S Ghazi; G Syed; T Pasha; G Gmati; H Salama; O Ali; K A Abuelgasim; M Al-Zahrani; A Hejazi; A Al Askar Journal: Bone Marrow Transplant Date: 2017-07-10 Impact factor: 5.483
Authors: Craig H Moskowitz; Joachim Yahalom; Andrew D Zelenetz; Zhigang Zhang; Daniel Filippa; Julie Teruya-Feldstein; Tarun Kewalramani; Alison J Moskowitz; Robert David Rice; Jocelyn Maragulia; Jill Vanak; Tanya Trippett; Paul Hamlin; Steven Horowitz; Ariela Noy; Owen A O'Connor; Carol Portlock; David Straus; Stephen D Nimer Journal: Br J Haematol Date: 2010-01-18 Impact factor: 6.998